<DOC>
	<DOCNO>NCT00239057</DOCNO>
	<brief_summary>The aim study evaluate addition EC-MPS CsA-ME allow safe withdrawal concomitant corticosteroid therapy long-term maintenance renal allograft recipient . All patient core study interested treat EC-MPS include open-label extension study collect information long-term safety , tolerability efficacy drug .</brief_summary>
	<brief_title>Study Enteric-coated Mycophenolate Sodium Maintenance Therapy Patients With Renal Transplant Receiving Cyclosporine Microemulsion Steroids ,</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Inclusion criterion 1 . Male female , 18 year age old . 2 . Recipients first secondary cadaver , live relate unrelated donor kidney transplant perform least 6 month screening ( Visit 1 ) 3 . Patients currently receive CsAME corticosteroid ( least 5 mg prednisone equivalent ) least 3 month prior Screening , without Mycophenolate mofetil azathioprine . 4 . Serum creatinine level &lt; 2.3 mg/dL ( =204 Âµmol/L ) screen baseline 5 . Stable kidney function , i.e . increase serum creatinine le 20 % last 3 month screen baseline ( baseline value compare value obtain screen ) Exclusion Criteria 1 . Multiorgan recipient ( e.g. , kidney pancreas , double kidney ) previous transplant organ different kidney 2 . Patients whit second transplant reject first one immunological reason relapse autoimmune disease lead endstage renal failure 3 . Histological evidence acute rejection treatment acute rejection within three month prior Screening , histological sign clinical sign chronic rejection ( significant proteinuria , i.e . &gt; 300 mg/24 hour . 4 . Patients maintenance steroid therapy disease ( i.e . autoimmune disease , Lupus ) . 5 . Patients know hypersensitivity ECMPS component formulation ( e.g. , lactose ) 6 . Patients thrombocytopenia ( &lt; 75,000/mm3 ) , absolute neutrophil count &lt; 1,500/mm3 and/or leukocytopenia ( &lt; 4,000/mm3 ) , and/or anemia ( hemoglobin &lt; 9.0 g/dL ) prior Screening visit . 7 . Patients receive investigational drug within two week prior Screening visit . 8 . Patients history malignancy within last five year , except excise squamous basal cell carcinoma skin . 9 . Females childbearing potential planning become pregnant , pregnant and/or lactating , unwilling use effective mean contraception 10 . Presence clinically significant infection require continued therapy , severe diarrhea , active peptic ulcer disease , uncontrolled diabetes mellitus would interfere appropriate conduct study . 11 . Any change immunosuppressive regimen due graft malfunction , know clinically significant physical and/or laboratory change 2 month prior Screening visit . 12 . Known positivity HIV , HBsAg 13 . Active viral hepatitis , show liver function test ( AST ALT ) high twice upper limit normality 14 . Evidence drug and/or alcohol abuse Other inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Renal transplantation , EC-MPS</keyword>
</DOC>